245 related articles for article (PubMed ID: 30600675)
1. Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma.
Kim BH; Park JW; Kim JS; Lee SK; Hong EK
Gut Liver; 2019 May; 13(3):342-348. PubMed ID: 30600675
[TBL] [Abstract][Full Text] [Related]
2. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.
Yamada T; Abei M; Danjoh I; Shirota R; Yamashita T; Hyodo I; Nakamura Y
BMC Cancer; 2015 Apr; 15():260. PubMed ID: 25885470
[TBL] [Abstract][Full Text] [Related]
3. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
[TBL] [Abstract][Full Text] [Related]
6. ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma.
Tanaka K; Tomita H; Hisamatsu K; Nakashima T; Hatano Y; Sasaki Y; Osada S; Tanaka T; Miyazaki T; Yoshida K; Hara A
Oncotarget; 2015 Sep; 6(28):24722-32. PubMed ID: 26160842
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
[TBL] [Abstract][Full Text] [Related]
8. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
9. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Marisi G; Cucchetti A; Ulivi P; Canale M; Cabibbo G; Solaini L; Foschi FG; De Matteis S; Ercolani G; Valgiusti M; Frassineti GL; Scartozzi M; Casadei Gardini A
World J Gastroenterol; 2018 Sep; 24(36):4152-4163. PubMed ID: 30271080
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
11. miR-589-5p inhibits MAP3K8 and suppresses CD90
Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
[TBL] [Abstract][Full Text] [Related]
12. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Godin C; Bodeau S; Saidak Z; Louandre C; François C; Barbare JC; Coriat R; Galmiche A; Sauzay C
Oncol Rep; 2019 Mar; 41(3):2041-2050. PubMed ID: 30569112
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma.
Hirata H; Sugimachi K; Takahashi Y; Ueda M; Sakimura S; Uchi R; Kurashige J; Takano Y; Nanbara S; Komatsu H; Saito T; Shinden Y; Iguchi T; Eguchi H; Atsumi K; Sakamoto K; Doi T; Hirakawa M; Honda H; Mimori K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1402-9. PubMed ID: 25404478
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models.
Zhao Q; Zhou H; Liu Q; Cao Y; Wang G; Hu A; Ruan L; Wang S; Bo Q; Chen W; Hu C; Xu D; Tao F; Cao J; Ge Y; Yu Z; Li L; Wang H
Oncotarget; 2016 Jul; 7(30):47431-47443. PubMed ID: 27329727
[TBL] [Abstract][Full Text] [Related]
16. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90.
Yoshida M; Yamashita T; Okada H; Oishi N; Nio K; Hayashi T; Nomura Y; Hayashi T; Asahina Y; Ohwada M; Sunagozaka H; Takatori H; Colombo F; Porretti L; Honda M; Kaneko S
Sci Rep; 2017 Sep; 7(1):11292. PubMed ID: 28900199
[TBL] [Abstract][Full Text] [Related]
18. The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations.
Luong AB; Do HQ; Tarchi P; Bonazza D; Bottin C; Cabral LKD; Tran LDC; Doan TPT; Crocè LS; Pham HLT; Tiribelli C; Sukowati CHC
Cells; 2020 Dec; 9(12):. PubMed ID: 33322687
[TBL] [Abstract][Full Text] [Related]
19. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
